{'fraction_non_alphanumeric': 0.05133767172812726, 'fraction_numerical': 0.038322487346348515, 'mean_word_length': 5.017391304347826, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Induction of apoptosis in glioma cell lines by TRAIL/Apo‐2l

TRAIL/Apo‐2L, a novel cytokine, is a member of the tumor necrosis factor (TNF) family and serves as an extracellular signal triggering apoptosis. TRAIL/Apo‐2L is capable of killing various transformed cells but not unstimulated primary T cells. In this study, five human glioma cells (U87, U118, U178, U563, and A172) were examined for their susceptibility to the apoptotic effects of TRAIL/Apo‐2L. TRAIL/Apo‐2L cDNA was isolated by RT‐PCR, and recombinant TRAIL/Apo‐2L protein was purified by the pMAL‐c2 system (New England Biolabs, Beverly, MA). Exposure of A172 cells to bacterially expressed soluble TRAIL/Apo‐2L fusion protein at a concentration of 1 μg/ml resulted in significant cell death over a 24‐h period. Three experiments were performed to suggest that the TRAIL/Apo‐2L killing was through the induction of apoptosis of A172 target cells. In addition, the expression of TRAIL/Apo‐2L in different glioma cells was found to be variable, and TRAIL/Apo‐2L–induced apoptosis was in a cell type‐dependent manner. Some correlation between the susceptibility to TRAIL/Apo‐2L and the expression level of one of its cognate receptors, DR4, was observed. In addition, cycloheximide worked synergistically with TRAIL/Apo‐2L to induce apoptosis in glioma cells. J. Neurosci. Res. 61:464–470, 2000. © 2000 Wiley‐Liss, Inc.